IP Library › Patent Application 18807610
Patent Application
App. No. 18/807,610

FUSION PROTEINS AND METHODS THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/807,610
Abstract

The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Claims (23)

1 . A method for treating a FGFR1-TACC1 fusion associated cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of AZD4547, or NVP-BGJ398, or a combination thereof, wherein the subject has a FGFR1-TACC1 fusion associated cancer, wherein the FGFR1-TACC1 fusion comprises a tyrosine kinase domain of FGFR1 fused to the TACC domain of TACC1.

2 . The method of claim 1 , wherein the subject has FGFR1-TACC1 fusion associated epithelial cancer, glioma, glioblastoma multiforme, breast cancer, lung cancer, prostate cancer, bladder carcinoma, squamous lung carcinoma, head and neck carcinoma or colorectal carcinoma.

3 . The method of claim 1 , wherein the subject has FGFR1-TACC1 fusion associated epithelial cancer.

4 . The method of claim 1 , wherein the subject has FGFR1-TACC1 fusion associated glioblastoma multiforme.

5 . The method of claim 1 , wherein the subject has FGFR1-TACC1 fusion associated glioma.

6 . The method of claim 4 , wherein the subject does not have mutations in IDH1 or IDH2 genes.

7 . The method of claim 1 , wherein the method comprises administering to the subject an effective amount of AZD4547.

8 . The method of claim 1 , wherein the method comprises administering to the subject an effective amount of NVP-BGJ398.

9 . The method of claim 1 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 88.

10 . The method of claim 1 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 150.

11 . A method for treating a FGFR1-TACC1 fusion associated cancer in a subject in need thereof, the method comprising:

(b) detecting whether or not a biological sample from the subject has a FGFR1-TACC1 fusion, wherein the FGFR1-TACC1 fusion comprises a tyrosine kinase domain of FGFR1 fused to the TACC domain of TACC1; and

(c) administering to the subject an effective amount of NVP-BGJ398, if in the subject has a FGFR1-TACC1 fusion protein.

12 . A method for treating a FGFR3-TACC3 fusion associated cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of AZD4547, wherein the subject has a FGFR3-TACC3 fusion associated cancer, wherein the FGFR3-TACC3 fusion comprises a tyrosine kinase domain of FGFR3 fused to the TACC domain of transforming acidic coiled-coil-containing (TACC)-3.

13 .- 28 . (canceled)

29 . The method of claim 11 , wherein the subject does not have mutations in IDH1 or IDH2 genes.

30 . The method of claim 11 , wherein the method further comprises administering to the subject an effective amount of AZD4547.

31 . The method of claim 11 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 88.

32 . The method of claim 11 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 150.

33 . The method of claim 4 , wherein the method comprises administering to the subject an effective amount of AZD4547.

34 . The method of claim 4 , wherein the method comprises administering to the subject an effective amount of NVP-BGJ398.

35 . The method of claim 4 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 88.

36 . The method of claim 4 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 150.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2025
From: IAVARONE, ANTONIO; LASORELLA, ANNA; RABADAN, RAUL
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 070783/0959 →